Your browser is no longer supported. Please, upgrade your browser.
ALLO Allogene Therapeutics, Inc. monthly Stock Chart
ALLO [NASD]
Allogene Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.13 Insider Own1.60% Shs Outstand127.14M Perf Week-2.62%
Market Cap4.51B Forward P/E- EPS next Y-2.44 Insider Trans-42.09% Shs Float70.34M Perf Month-11.63%
Income-242.70M PEG- EPS next Q-0.58 Inst Own61.80% Short Float14.32% Perf Quarter-9.97%
Sales- P/S- EPS this Y-4.90% Inst Trans-3.26% Short Ratio14.78 Perf Half Y-36.72%
Book/sh8.80 P/B3.55 EPS next Y-14.10% ROA-25.00% Target Price52.25 Perf Year11.34%
Cash/sh5.83 P/C5.36 EPS next 5Y- ROE-27.60% 52W Range17.43 - 55.00 Perf YTD20.21%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-45.13% Beta-
Dividend %- Quick Ratio17.00 Sales past 5Y- Gross Margin- 52W Low73.15% ATR1.87
Employees264 Current Ratio17.00 Sales Q/Q- Oper. Margin- RSI (14)38.85 Volatility4.75% 5.44%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.90% Profit Margin- Rel Volume0.73 Prev Close31.23
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume681.49K Price30.18
Recom1.90 SMA20-6.35% SMA50-15.13% SMA200-11.69% Volume367,759 Change-3.36%
Oct-23-20Initiated RBC Capital Mkts Outperform $55
Jun-01-20Downgrade Raymond James Outperform → Mkt Perform
May-29-20Reiterated H.C. Wainwright Buy $42 → $55
May-19-20Upgrade ROTH Capital Neutral → Buy $26 → $60
May-15-20Upgrade Guggenheim Neutral → Buy
May-14-20Reiterated H.C. Wainwright Buy $35 → $42
May-14-20Downgrade SunTrust Buy → Hold $29 → $32
Apr-13-20Initiated SunTrust Buy $29
Mar-13-20Initiated H.C. Wainwright Buy $35
Mar-05-20Initiated Stifel Hold $27
Feb-24-20Initiated Berenberg Hold $27
Dec-18-19Initiated JMP Securities Mkt Outperform $37
Nov-04-19Initiated Canaccord Genuity Buy $36
Aug-09-19Initiated BTIG Research Buy $37
Jun-05-19Initiated ROTH Capital Neutral $26
May-31-19Initiated Guggenheim Neutral
May-23-19Initiated Stifel Hold
Mar-29-19Initiated Piper Jaffray Overweight $50
Mar-15-19Initiated Raymond James Outperform
Mar-14-19Initiated William Blair Outperform
Nov-12-20 08:30AM  
Nov-08-20 11:04AM  
Nov-04-20 12:44PM  
09:52AM  
09:03AM  
07:30AM  
06:45AM  
Oct-27-20 08:30AM  
Oct-24-20 08:55AM  
Oct-21-20 10:02AM  
Oct-15-20 08:00AM  
Sep-29-20 06:48PM  
Sep-04-20 11:31AM  
Sep-02-20 08:30AM  
Aug-06-20 11:19AM  
Aug-05-20 07:30AM  
Jul-29-20 09:27AM  
Jul-28-20 08:30AM  
Jul-20-20 08:30AM  
Jul-15-20 07:55AM  
Jul-07-20 08:30AM  
Jul-05-20 03:31PM  
Jul-01-20 10:54AM  
08:30AM  
Jun-26-20 03:30PM  
11:30AM  
Jun-22-20 04:30PM  
08:30AM  
Jun-14-20 11:38AM  
07:00AM  
Jun-10-20 11:30AM  
Jun-05-20 11:32AM  
Jun-03-20 08:30AM  
Jun-02-20 07:14AM  
Jun-01-20 09:05PM  
11:52AM  
06:30AM  
06:02AM  
May-29-20 10:32AM  
08:00AM  
May-28-20 11:21AM  
May-27-20 10:02AM  
May-26-20 04:30PM  
May-22-20 11:30AM  
May-19-20 08:55AM  
May-18-20 09:22AM  
May-15-20 07:49AM  
May-14-20 01:06PM  
04:20AM  
May-13-20 05:00PM  
10:54AM  
May-11-20 08:30AM  
May-07-20 10:51AM  
08:01AM  
May-06-20 07:30AM  
May-05-20 11:45AM  
11:40AM  
08:43AM  
Apr-29-20 11:54AM  
11:43AM  
Apr-28-20 04:39PM  
Apr-27-20 08:30AM  
Apr-22-20 07:15AM  
Apr-17-20 11:30AM  
Apr-16-20 12:00PM  
Apr-01-20 08:30AM  
Mar-28-20 09:10PM  
Mar-24-20 07:00AM  
Mar-23-20 12:00PM  
Mar-20-20 08:54AM  
Mar-17-20 06:30AM  
Mar-16-20 12:09AM  
Mar-02-20 06:15AM  
Mar-01-20 07:15AM  
Feb-27-20 04:30AM  
Feb-19-20 08:30AM  
Feb-06-20 08:30AM  
Jan-13-20 06:00AM  
Jan-02-20 08:30AM  
Dec-20-19 05:16PM  
Nov-11-19 08:30AM  
Nov-06-19 09:02AM  
Nov-05-19 07:30AM  
06:28AM  
Oct-29-19 08:30AM  
Oct-25-19 11:12AM  
Oct-18-19 11:22AM  
Oct-03-19 05:53PM  
Sep-19-19 08:00AM  
06:59AM  
Sep-18-19 05:33PM  
Sep-03-19 08:30AM  
Aug-20-19 10:00AM  
Aug-07-19 11:24PM  
07:30AM  
Aug-05-19 06:00AM  
Jul-29-19 08:30AM  
Jul-16-19 08:00AM  
Jun-22-19 07:30AM  
Jun-04-19 07:45AM  
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHMIDT ERIC THOMASChief Financial OfficerNov 16Sale32.8815,000493,1461,182,595Nov 18 04:36 PM
SCHMIDT ERIC THOMASChief Financial OfficerOct 15Sale40.4915,000607,3921,197,595Oct 16 06:55 PM
MOORE ALISONChief Technical OfficerOct 13Option Exercise2.2711,03125,040119,401Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 13Sale42.0011,031463,302108,370Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 12Option Exercise2.2724,23355,009132,603Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 12Sale42.0024,2331,017,786108,370Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 09Option Exercise2.2730,19968,552147,879Oct 09 05:49 PM
MOORE ALISONChief Technical OfficerOct 09Sale41.0039,5091,619,869108,370Oct 09 05:49 PM
MOORE ALISONChief Technical OfficerOct 08Option Exercise2.275,06511,498122,745Oct 09 05:49 PM
MOORE ALISONChief Technical OfficerOct 08Sale41.005,065207,665117,680Oct 09 05:49 PM
Amado RafaelEVP of R&D and CMOOct 07Sale39.4016,538651,515111,677Oct 08 05:10 PM
Bhavnagri VeerGeneral CounselOct 06Option Exercise2.2710,00022,700363,902Oct 08 05:01 PM
MOORE ALISONChief Technical OfficerOct 06Option Exercise2.2735,26480,049161,536Oct 08 05:03 PM
MOORE ALISONChief Technical OfficerOct 06Sale40.0044,5741,782,960117,680Oct 08 05:03 PM
Bhavnagri VeerGeneral CounselOct 06Sale40.0010,000400,000353,902Oct 08 05:01 PM
Bhavnagri VeerGeneral CounselOct 01Option Exercise2.2725,00056,750378,902Oct 02 04:42 PM
Bhavnagri VeerGeneral CounselOct 01Sale36.5225,000912,913353,902Oct 02 04:42 PM
Amado RafaelEVP of R&D and CMOOct 01Sale36.379,752354,662128,215Oct 02 04:40 PM
SCHMIDT ERIC THOMASChief Financial OfficerSep 21Sale35.3015,000529,5451,212,595Sep 22 04:48 PM
Bhavnagri VeerGeneral CounselSep 01Option Exercise2.2725,00056,750378,902Sep 03 04:12 PM
Bhavnagri VeerGeneral CounselSep 01Sale35.3625,000883,966353,902Sep 03 04:12 PM
MOORE ALISONChief Technical OfficerAug 13Option Exercise2.2732,45173,664126,272Aug 14 04:04 PM
TPG Group Holdings (SBS) Advis10% OwnerAug 07Sale37.4113,291497,23618,716,306Aug 10 04:34 PM
TPG Group Holdings (SBS) Advis10% OwnerAug 06Sale37.5024,154905,79418,729,597Aug 10 04:34 PM
Bhavnagri VeerGeneral CounselAug 03Option Exercise2.2725,00056,750385,455Aug 05 05:09 PM
Bhavnagri VeerGeneral CounselAug 03Sale36.8931,5531,164,121353,902Aug 05 05:09 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 30Sale42.2159,7472,522,05219,716,306Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 29Sale43.2724,9041,077,54419,776,053Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 26Sale44.0150022,00519,800,957Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 25Sale44.1972,3593,197,32719,801,457Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 24Sale43.9315,269670,71419,873,816Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 23Sale43.98132,2255,814,61019,889,085Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 22Sale42.83172,4257,384,72120,021,310Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 19Sale42.0447,7672,008,30620,193,735Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 18Sale42.1494,6003,986,59520,241,502Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 17Sale42.1887,3193,683,48220,336,102Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 16Sale42.20174,5117,364,67820,423,421Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 15Sale42.14129,1545,442,88520,597,932Jun 17 06:13 PM
Belldegrun ArieDirectorJun 04Buy47.00146,3826,879,9541,798,163Jun 04 04:04 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 04Sale47.111,81885,63820,727,086Jun 05 05:43 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 03Sale47.40487,40223,102,51420,728,904Jun 05 05:43 PM
SCHMIDT ERIC THOMASChief Financial OfficerMar 16Sale19.735,450107,50847,257Mar 18 04:32 PM
MOORE ALISONChief Technical OfficerMar 16Sale19.193,75071,98063,021Mar 18 04:32 PM
Chang David DPresident and CEOMar 16Sale19.3120,335392,6152,214,914Mar 18 04:31 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.